EPS for BioSyent Inc. (RX) Expected At $0.12

November 10, 2018 - By Dolores Ford

Analysts expect BioSyent Inc. (CVE:RX) to report $0.12 EPS on November, 21.They anticipate $0.03 EPS change or 33.33 % from last quarter’s $0.09 EPS. V_RX’s profit would be $1.74 million giving it 18.85 P/E if the $0.12 EPS is correct. After having $0.11 EPS previously, BioSyent Inc.’s analysts see 9.09 % EPS growth. The stock decreased 1.63% or $0.15 during the last trading session, reaching $9.05. About 2,500 shares traded. BioSyent Inc. (CVE:RX) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company has market cap of $131.42 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. It has a 23.82 P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>